Management of Spravato-Induced Anxiety
For anxiety occurring during or immediately after Spravato (esketamine) administration, benzodiazepines—specifically lorazepam 0.5-1 mg orally or sublingually—are the most appropriate pharmacologic intervention, though non-pharmacologic strategies should be attempted first.
Understanding Spravato-Related Anxiety
Anxiety is a recognized adverse effect of esketamine treatment, often occurring as part of the dissociative experience during the immediate post-administration period. The Spravato FDA label 1 explicitly warns that "an initial adverse effect of SSRIs can be anxiety or agitation" and notes dissociation as a common side effect requiring 2-hour post-treatment monitoring in certified healthcare settings.
Treatment Algorithm
First-Line: Non-Pharmacologic Interventions
Start with reassurance and environmental modifications before considering medication. A case report 2 demonstrated that a 64-year-old woman experiencing dissociative episodes with associated anxiety and confusion during esketamine treatment achieved "notable improvement" simply by listening to music of her choice during treatment sessions, combined with staff reassurance. This approach should be standard practice.
Key non-pharmacologic strategies:
- Patient education about expected transient dissociative symptoms before treatment
- Calming music during and after administration
- Verbal reassurance from trained staff
- Adequate lighting and orientation cues
- Comfortable, quiet environment during the mandatory 2-hour observation period
Second-Line: Pharmacologic Management
If non-pharmacologic measures fail and anxiety is severe or distressing, benzodiazepines are indicated. Based on established guidelines for managing acute anxiety in medical settings 3, 4:
Lorazepam dosing:
- 0.5-1 mg orally or sublingually as needed
- Can be given during the observation period if anxiety persists
- Maximum 4 mg in 24 hours (reduce to 2 mg maximum in elderly/debilitated patients)
- Oral tablets can be used sublingually for faster onset 3
Alternative if unable to take oral medication:
- Midazolam 2.5 mg subcutaneously or IV (reduce to 0.5-1 mg if co-administered with other sedating medications) 4
Critical Safety Considerations
Important caveats when using benzodiazepines with esketamine:
Respiratory depression risk: The ESMO guidelines 4 specifically warn about "fatalities reported with concurrent use of benzodiazepines with high-dose olanzapine" due to oversedation and respiratory depression. While this refers to olanzapine, the principle applies—use the lowest effective benzodiazepine dose when combining with esketamine.
Avoid routine prophylactic use: Benzodiazepines should be used PRN (as needed) for breakthrough anxiety, not routinely scheduled 4.
Monitor carefully: Patients receiving benzodiazepines during the post-esketamine observation period require enhanced monitoring for sedation and respiratory status.
Contraindications: Avoid benzodiazepines in patients with severe pulmonary insufficiency, severe liver disease, or myasthenia gravis 4.
Alternative Considerations
SSRIs/SNRIs for persistent anxiety: If anxiety becomes a recurring problem across multiple esketamine sessions rather than acute episodes, consider optimizing the concurrent oral antidepressant. The Spravato label 1 indicates all patients should be on a concomitant SSRI or SNRI (duloxetine, escitalopram, sertraline, or venlafaxine), which may help reduce baseline anxiety over time.
Dose adjustment: If anxiety consistently occurs with 84 mg doses, consider maintaining the patient at 56 mg 1. The clinical trials showed that dosing was "individualized based on efficacy and tolerability" with few patients (<10%) requiring dose reduction.
Evidence Quality Note
The evidence for managing esketamine-induced anxiety specifically is limited to case reports 2 and extrapolation from general anxiety management guidelines 3, 4. Recent systematic reviews 5, 6 actually suggest esketamine may reduce anxiety symptoms overall in depression and surgical patients, but acute transient anxiety during administration remains a recognized phenomenon requiring management.
The approach prioritizes patient safety and quality of life by starting with low-risk non-pharmacologic interventions, reserving benzodiazepines for cases where anxiety significantly impairs the treatment experience or patient safety.